Vaccines: Should Covid-19 trump patent protections?
President Biden dialed up the pressure on pharmaceutical companies to help other countries fight the pandemic, said Josh Wingrove in Bloomberg.com, stunning allies last week by calling for patent protections on Covid-19 vaccines to be lifted. In a “reversal of long-standing U.S. policy that its companies’ intellectual property is sacrosanct,” U.S. Trade Representative Katherine Tai said the administration would “back a World Trade Organization process to try to reach” agreement for patent waivers to speed the worldwide vaccination effort. So far, though, the WTO is not close to a consensus on such waivers, and Biden’s support for them could turn out be largely symbolic, because France and Germany have said they would oppose rolling back patent rights.
Biden is right, said Katie Gallogly-Swan in The New Republic. “We will continue to play catch-up” with this virus unless we are able to produce vaccines “to scale, quickly, and without affordability barriers.” Intellectual-property protections are “a huge barrier to this task.” Those patents are mainly in place to “protect the profits of pharmaceutical giants.” Moderna earned $1.22 billion in the first quarter, while Pfizer counted roughly $900 million in profits. Biden criticized Donald Trump for his “vaccine isolationism,” said Michelle Goldberg in The New York Times. Now, India, South Africa, and dozens of other countries are begging for this “temporary change to global trade rules to help them defend themselves.” A waiver won’t automatically solve the vaccine shortage, but it’s a start.
In record time, Pfizer created and distributed a drug “that effectively alleviated the threat of the most deadly virus we’ve faced in over a century,” David Harsanyi in NationalReview .com. “So, naturally, progressives want to punish Pfizer” by stripping its patents. Liberal Democrats want to use Pfizer’s profits as justification for “state-sponsored theft.” This patent heist won’t end well, said The Wall Street Journal in an editorial. U.S. and European drug companies have already voluntarily entered into dozens of licensing agreements to scale up production in low-income countries, but producing vaccines safely takes time. Meanwhile, Biden is willing to hand over “America’s crown pharmaceutical jewels.” The U.S. “has a competitive advantage in biotech” that will disappear if investors “think their own government will betray them under political pressure.”
It’s telling that Moderna says it won’t enforce its Covid-related patents, said Sarah Jane Tribble and Arthur Allen in Kaiser
Health News. “No known independent producer” has even attempted “to replicate the company’s mRNA vaccine,” which relies on a sophisticated process developed over 10 years. Even Johnson & Johnson, which uses more conventional techniques, “assessed nearly 100 production sites” and selected fewer than a dozen partners to share the requisite technology, training, and raw materials—and it has still been the victim of production mistakes. “In the best-case scenario, sharing patents is only a tiny step in the vastly complex work of making a Covid vaccine.”